Een zweed op Linkedin vroeg zich een jaar geleden af of de medicijnen van Abliva ook een rol kunnen spelen bij andere ziektes, zoals ME/CFS en post-Covid.
Interessante suggestie om hier eens over te delibereren…
———
I have followed your journey for many years and I hope, of course, that it will go well. NAD+ may be needed for a variety of other diseases, including ME/CFS and post-COVID.
KL1333 is very interesting since the problem is that, so far, we do not know exactly which precursors are needed for the best results, although Nicotinamide Riboside has been shown to play an important role for NAD+. But probably more synergists are needed.
Your other drug candidate, NV354, might be more interesting since, from what I understand, this prodrug increases the level of succinate, which is very important in energy metabolism.
I believe both of these drug candidates are very important to test on patients with ME/CFS and post-COVID, as both groups share many problems with those suffering from primary mitochondrial diseases. I hope you keep this in mind